Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients-A pharmacoeconomic analysis

Clinical and Applied Thrombosis/Hemostasis

Volumn 17, Issue 5, 2011, Pages 454-465

  Wilbur, Kerry ^a   Lynd, L D ^b   Sadatsafavi, M ^b  

^a QATAR UNIVERSITY   (Qatar)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

Canadian; cost effective analysis; hospitalized medicine patients; low molecular weight heparin; thromboprophylaxis; unfractionated heparin

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; NADROPARIN; WARFARIN;

AGED; ARTICLE; BLEEDING; CANADA; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DEATH; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HIGH RISK PATIENT; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LENGTH OF STAY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

CANADA; COSTS AND COST ANALYSIS; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITALIZATION; HUMANS; MALE; MODELS, THEORETICAL; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 80053608750     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029610376935     Document Type: Article

References (70)

1. Park B, Massina L, Dargon P, Huang W, Ciocca R, Anderson FA. Recent trends in clinical outcome and resource utilization for pulmonary embolism in the United States: findings from the nationwide inpatient sample. Chest. 2009 ; 136 (4). 983-990
2. Goldhaber SZ. Epidemiology of pulmonary embolism. Semin Vasc Med. 2001 Nov ; 1 (2). 213-20
3. Prandoni P, Lensing A, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996 ; 125 (1). 1-7
4. Kahn SR, M'Lan CE, Lamping DL, et al. The influence of venous thromboembolism on quality of life and severity of chronic venous disease. J Thromb Haemost. 2004 ; 2 (12). 2146-2151 (Pubitemid 40185774)
5. Goldhaber SZ, Dunn K, MacDougall RC. New onset venous thromboembolism among hospitalized patients at Brigham and Women's hospital is caused more often by prophylaxis failure than by withholding treatment. Chest. 2000 ; 118 (6). 1680-1684 (Pubitemid 32001795)
6. Geerts WH, Bergqvist D, Pineo GH, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008 ; 133 (3 suppl). 381S - 453S (Pubitemid 351894916)
7. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998 ; 158 (6). 585-593 (Pubitemid 28144815)
8. Kierkergaard A, Norgren L, Olssom CG, Castenfors J, Persson G, Persson S. Incidence of deep vein thrombosis in bedridden non surgical patients. Acta Med Scand. 1987 ; 222 (5). 409-414 (Pubitemid 18013137)
9. Belch JJ, Lowe GDO, Ward AG, Forbes CD, Prentice CRM. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J. 1981 ; 26 (2). 115-117 (Pubitemid 11032070)
10. Samana MM, Cohen AT, Darmon JV, et al. A comparison of enoxaparin with placebo for the prevention venous thromboembolism in acutely ill medicine patients. N Engl J Med. 1999 Sep 9 ; 341 (11). 793-800 (Pubitemid 29420474)
11. Heit JA, Silverstein MD, Mohr DN, Patterson TM, O'Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000 ; 160 (6). 109-15
12. Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003 ; 107 (23 suppl 1). 9-16
13. Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost. 2004 ; 2 (12). 2156-2161 (Pubitemid 40185776)
14. Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX study. Arch Intern Med. 2004 ; 164 (9). 963-968 (Pubitemid 38581515)
15. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine patients with unfractionated or low-molecular-weight heparins: a meta-analysis of randomized clinical trials. Thromb Haemost. 2000 ; 83: 14-19 (Pubitemid 30045469)
16. Etchells E, McLeod RS, Geerts W, Barton P, Detsky AS. Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery. Arch Intern Med. 1999 ; 159 (11). 1221-1228 (Pubitemid 29269862)
17. Anderson DR, O'Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med. 1993 ; 119 (11). 1105-1112 (Pubitemid 23359925)
18. Planes A, Vochelle N, Fafola M. Venous thromboembolism prophylaxis in orthopedic surgery: knee surgery. Semin Thromb Hemost. 1999 ; 25 (suppl 3). 73-77 (Pubitemid 29517036)
19. Shorr AF, Ramage AS. Enoxaparin for thromboprophylaxis after major trauma: potential cost implications. Crit Care Med. 2001 ; 29 (9). 1659-1665 (Pubitemid 32848361)
20. Lynd L, Goeree R, Crowther MA, O'Brien BJ. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep vein thrombosis following major trauma. Can J Clin Pharmacol. 2007 ; 14 (2). e215 - e226
21. Wade WE, Chisholm MA. Cost-effectiveness analysis of deep vein thrombosis prophylaxis in internal medicine patients. Thromb Res. 1999 ; 94 (1). 65-68 (Pubitemid 29170402)
22. Lloyd AC, Anderson PM, Quinlan DJ, Bearne A. Economic evaluation of the use of enoxaparin for thrombopropylaxis in acutely ill medical patients. J Med Econ. 2001 ; 4: 99-113 (Pubitemid 32625300)
23. Offord R, Lloyd AC, Anderson P, Bearne A. Economic evaluation of enoxaparin for prevention of venous thromboembolism in acutely ill medicine patients. Pharm World Sci. 2004 ; 26 (4). 214-220 (Pubitemid 39060901)
24. Schadlich PK, Kentsch M, Weber M, et al. Cost-effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany. Pharmacoeconomics. 2006 ; 24 (6). 571-591 (Pubitemid 43886268)
25. Shorr AI, Jackson WL, Wiss BM, Moores LK. Low molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medicine patients: results from a cost effective analysis. Blood Coagul Fibrinolysis. 2007 ; 18(: 309-316 (Pubitemid 46699406)
26. American Public Health Association. Deep vein thrombosis: advancing awareness to protect patient lives-White paper. http://www.apha.org/ppp/DVT- White-Paper.pdf
27. US Department of Health and Human Services. The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism, 2008.
28. Stark JE, Kilzer WJ. Venous thromboembolic prophylaxis in hospitalized medical patients. Ann Pharmacother. 2004 ; 38 (1). 36-40 (Pubitemid 38018002)
29. Patel K, Loewen P, Wilbur K. A retrospective evaluation of adherence to guidelines for prevention of thromboembolic events in general medicine inpatients. Can J Hosp Pharm. 2006 ; 59: 259-263
30. Aujesky D, Guignard E, Pannatier A, Cornuz J. Pharmacological thromboembolic prophylaxis in a medical ward: room for improvement. J Gen Intern Med. 2002 ; 17 (10). 788-791 (Pubitemid 35286244)
31. Carroll DN, Hudson EB. Venous thromboembolism prophylaxis conversion in nonsurgical patients. Ann Pharmacother. 2003 ; 37 (9). 1194-1196 (Pubitemid 37040207)
32. Deitelzweig SB, Vanscoy GJ, Niccolai CS, Rihn TL. Venous thromboembolism prevention with LMWHs in medical and orthopedic surgery patients. Ann Pharmacother. 2003 ; 37 (3). 402-411 (Pubitemid 36249644)
33. O'Brien B, Levine M, William A, et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med. 1999 ; 159 (19). 2298-2304 (Pubitemid 29501529)
34. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep vein thrombosis. A cost-effectiveness analysis. Ann Intern Med. 1999 ; 130 (10). 789-99 (Pubitemid 29231147)
35. Hull RD, Pineo GF, Raskob . The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Haemostasis. 1998 ; 28 (suppl 3). 8-16 (Pubitemid 29049316)
36. Lamy A, Wang X, Kent R, Smith KM, Gofni A. Economic evaluation of the MEDENOX trial: a Canadian perspective. Can J Respir J. 2002 ; 9 (3). 169-177 (Pubitemid 34863634)
37. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin. N Engl J Med. 1995 ; 332 (20). 1330-1335
38. Locke CFS, Dooley J, Gerber J. Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar. Thrombosis Journal. 2005 ; 3 (1). 1-5
39. O'Brien BJ, Anderson DR, Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. CMAJ. 1994 ; 150 (7). 1083-90 (Pubitemid 24144105)
40. Mismetti P, Quenet S, Levine M, et al. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis. Chest. 2005 ; 128 (4). 2203-2210 (Pubitemid 41507560)
41. Attanasio E, Russo P, Carunchio G, Caprino L. Dermatan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer: a cost-effectiveness analysis. Pharmacoeconomics. 2001 ; 19 (1). 57-68 (Pubitemid 32113372)
42. Goodacre S, Sutton AJ, Sampson FC. Meta-analysis: the value of clinical assessment in the diagnosis of deep venous thrombosis. Ann Intern Med. 2005 ; 143 (2). 129-139
43. Kearon C, Julian JA, Newman TE, Ginsberg JS. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med. 1998 ; 128 (8). 663-677
44. Fedullo PF, Tapson VF. The evaluation of suspected pulmonary embolism. N E J Med. 2003 ; 349: 1247-1256 (Pubitemid 37152035)
45. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Mak. 1985 ; 5 (2). 157-177 (Pubitemid 16130640)
46. Kearon C, Julian JA, Newman TE, et al. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med. 1998 ; 128 (8). 663-677
47. Rodger MA, Bredeson CN, Jones G, et al. The bedside investigation of pulmonary embolism diagnosis study- A double-blind randomized trial comparing combinations of 3 bedside tests vs ventilation-perfusion scan for the initial investigation of suspected pulmonary embolism. Arch Intern Med. 2006 ; 166 (2). 181-187 (Pubitemid 43144941)
48. Graafsma YP, Prins MH, Lensing AWA, de Haan RJ, Huisman MV, Buller HR. Bleeding classification in clinical trials: observer variability and clinical relevance. Thromb Haemost. 1997 ; 78 (4). 1189-1192 (Pubitemid 27464584)
49. Mamdani MM, Weingarten CM, Stevenson JG. Thromboembolic prophylaxis in moderate-risk patients undergoing elective abdominal surgery: decision and cost-effectiveness analysis. Pharmacotherapy. 1996 ; 16 (6). 1111-1127 (Pubitemid 26403654)
50. Khan NA, Quan H, Bugar JM, Lemaire JB, Brant R, Ghali WA. Association of postoperative complications with hospital costs and length of stay in a tertiary care center. J Gen Intern Med. 2006 ; 21 (2). 177-180 (Pubitemid 43363675)
51. O'Brien JA, Caro JJ. Direct medical costs of managing deep vein thrombosis according to the occurrence of complications. Pharmacoeconomics. 2002 ; 20 (9). 603-615
52. Health Sciences Association of British Columbia. Collective Agreements. Health science professionals. [Online]. 2009 [cited 2008 Dec]; Available from: http://www.hsabc.org/content.php?id=9&sid=5
53. British Columbia Nurses' Union. Provincial Contract. Wage Grid. [Online]. 2009 [cited 2008 Dec]. Available from: http://www.bcnu.org/contracts-services/ default.htm
54. Vancouver, BC: British Columbia Medical Association ; 2003 :
55. Mcgarry LJ, Thompson D, Weinstein MC, Goldhaber SZ. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Manag Care. 2004 ; 10 (9). 632-642 (Pubitemid 39287373)
56. Statistics Canada. Consumer Price Index. [Online]. 2009 [cited 2008 Dec]; Available from: http://www.statcan.gc.ca/subjects-sujets/cpi-ipc/cpi-ipc-eng. htm
57. Kahn ZM, Lawson KA. Providing home infusion therapies in Texas: a time study. Infusion. 1996 ; 1: 30-43
58. Aujesky D, Stone RA, Kim S, Crick EJ, Fine MJ. Length of hospital stay and postdischarge mortality in patients with pulmonary embolism. a statewide perspective. Arch Intern Med. 2008 ; 168 (7). 706-712 (Pubitemid 351563953)
59. Botteman MF, Caprini J, Stephens JM, et al. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. Clin Ther. 2002 ; 24 (11). 1960-1986 (Pubitemid 35440962)
60. Schwarcz TH, Quick RC, Minion DJ, et al. Enoxaparin treatment in high-risk trauma patients limits the utility of surveillance venous duplex scanning. J Vasc Surg. 2001 ; 34 (3). 447-452 (Pubitemid 33661177)
61. Piazza G, Fanikos J, Zayaruzny M, Goldhaber SZ. Venous thromboembolic events in hospitalized medical patients. Thromb Haemost. 2009 ; 102: 505-510
62. Kahn SR, Ginsberg JS. Relationship between deep vein thrombosis and the postthrobotic syndrome. Arch Intern Med. 2004 ; 164 (1). 17-26 (Pubitemid 38067385)
63. Rodger MA, Bredeson C, Wells PS, Beck J, Kearns B, Huebsch LB. Cost-effectiveness of low molecular weight heparin and unfractionated heparin in treatments of deep vein thrombosis. CMAJ. 1998 ; 159: 931-938
64. Boucher M, Rodger M, Johnson JA, Tierney M. Shifting from inpatient to outpatient treatment of deep vein thrombosis in a tertiary care centre: a cost-minimization analysis. Pharmacotherapy. 2004 ; 23 (3). 301-309
65. Kleber FX, Witt C, Vogel G, et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J. 2003 ; 145 (4). 614-621 (Pubitemid 36403489)
66. High-alert medications and patient safety. Int J Qual Health Care. 2001 ; 13 (4). 339-340
67. Vanscoy GJ. The inevitability of change. Pharmacotherapy. 2004 ; 24 (8 Pt 2). 1015-1025
68. Wein L, Wein S, Haas SJ, Shaw J, Krum H. Pharmacological venous thromboembolism prophylaxis in hospitalized patients. A meta-analysis of randomized controlled trials. Arch Intern Med. 2007 ; 167 (14). 1476-1486 (Pubitemid 47124178)
69. Michota FA. Bridging the gap between evidence and practice in venous thromboembolism prophylaxis: the quality improvement process. J Gen Intern Med. 2007 ; 22 (12). 1762-70 (Pubitemid 350160337)
70. Nowbar S, Burkart KM, Gonzales R, et al. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcomes. Am J Med. 2004 ; 116: 1-7 (Pubitemid 38050019)